A Phase 3, Double-Blind, Randomized, Placebo Controlled, Parallel Group, Flexible Dose, 27 Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa... (TEMPO 3)